|
| ADVERSE DRUG REACTION REPORT |
|
| Year : 2021 | Volume
: 67
| Issue : 3 | Page : 158-163 |
DRESS syndrome induced by imatinib
S Kaur1, S Singh2, R Singh2, P Singla1
1 Department of Dermatology, Dayanand Medical College and Hospital, Ludhiana, Punjab, India
2 Department of Medical Oncology, Dayanand Medical College and Hospital, Ludhiana, Punjab, India
Correspondence Address:
S Kaur
Department of Dermatology, Dayanand Medical College and Hospital, Ludhiana, Punjab
India
 Source of Support: None, Conflict of Interest: None  | Check |
DOI: 10.4103/jpgm.JPGM_746_20
Drug rash with eosinophilia and systemic symptoms (DRESS syndrome) is a severe, potentially life-threatening drug-induced hypersensitivity reaction characterized by cutaneous eruptions, fever, diffuse lymphadenopathy, along with eosinophilia and elevated liver enzymes. The severity and potential organ damage associated with DRESS mandates withdrawing the offending drug and provide a suitable replacement. We report a 55-year-old man who developed prolonged fever, generalized maculopapular rash and facial edema after 3 weeks of starting imatinib for chronic myeloid leukemia (CML). A diagnosis of DRESS was confirmed by eosinophilia and skin biopsy findings, along with a consistent RegiSCAR score. Imatinib was stopped and he was initiated on low-dose steroids, which led to complete resolution of rash and eosinophilia. A rechallenge with imatinib was positive, and he was switched to dasatinib for further therapy, following which he attained an optimal molecular response. DRESS following imatinib has only been reported in eight patients so far. In this report we summarize the current evidence for managing DRESS and its impact on the treatment of CML.
[FULL TEXT] [PDF]*
|
